XML 38 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue by Product
 6 Months Ended
Jun. 30, 2020
Segment Reporting [Abstract]  
Revenue by Product Revenue by Product 
The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the Chief Executive Officer (the “CEO”). The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. 
The following table presents a summary of total product sales by these products: 
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
Product Sales by Product:
 
2020
 
2019
 
2020
 
2019
 
 
 
 
 
 
 
 
 
Bloxiverz
 
$
800

 
$
2,358

 
$
2,201

 
$
4,926

Vazculep
 
4,915

 
9,410

 
10,429

 
18,883

Akovaz
 
4,196

 
5,946

 
9,545

 
9,738

Other
 
180

 
(160
)
 
159

 
444

Total product sales
 
$
10,091

 
$
17,554

 
$
22,334

 
$
33,991



On June 30, 2020, we sold the hospital business. See Note 4: Disposition of the Hospital Business.